METTL3-mediated m6A Methylation Modification Promotes the Endothelial Cell Pyroptosis in Kawasaki Disease
简介:
- 作者: Bingbing Qiu, Chengyi Wang, Changdi Chen, Xuemin Zhu & Guanghua Liu
- 杂志: Applied Biochemistry and Biotechnology
- Doi: https://www.doi.org/10.1007/s12010-025-05441-8
- 出版日期: 2025/11/3
摘要
Kawasaki disease (KD) is classified as an acute febrile illness characterized primarily by systemic vasculitis. While the involvement of N6-methyladenosine (m6A) modification in various cardiovascular conditions has been established, its specific role in KD remains unexplored. This study aims to investigate the potential influence of m6A modification in KD and to elucidate the mechanisms involved. Clinically, 18 KD patients and 15 healthy volunteers were recruited. Reverse transcription-quantitative polymerase chain reactio (RT-qPCR) was performed to assess the expression of m6A-related enzymes. Lactate dehydrogenase (LDH) release, interleukin (IL)-1β and IL-18 concentrations were analyzed by commercial kits. Hoechst 33,342/PI staining was performed for cell death detection. Pyroptosis-related protein levels were detected by Western blot. RNA immunoprecipitation (RIP) and dual-luciferase reporter assays were performed to assess the interaction between methyltransferase-like protein 3 (METTL3) and Nod-like receptor (NLR) family CARD domain-containing protein 4 (NLRC4). Finally, a KD mouse model was induced by Candida albicans cell wall extracts. Results showed that serum from KD patients exhibited higher METTL3 expression. Additionally, KD serum-treated THP1 cells induced pyroptosis of human umbilical vein endothelial cells (HUVECs). Mechanistically, METTL3 promoted the stability of NLRC4 mRNA via m6A methylation. Furthermore, NLRC4 overexpression promoted pyroptosis in KD-treated HUVECs. Finally, METTL3 inhibition attenuated coronary arteritis and pyroptosis in a KD mouse model. In summary, this study concluded that METTL3-mediated m6A methylation modification promoted the endothelial cell pyroptosis in KD, which might provide a reference for the pathogenesis of KD.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。